Inventor · disambiguated record
Gianpietro Dotti
Also filed as: DOTTI GIANPIETRO
6 granted patents·22 pending applications·30 citations·filing 2011–2025
77Inventor score
Files withUNIV NORTH CAROLINA CHAPEL HILL10BAYLOR COLLEGE MEDICINE8METELITSA LEONID S3UNIV NORTH CAROLINA STATE2BRENNER MALCOLM1
Top patents by PatentIndex Score
28 records- 0189US10233226B2Methods and compositions for chimeric antigen receptor targeting cancer cellsUNIV NORTH CAROLINA CHAPEL HILL·Filed 2018·Granted Mar 19, 2019·3 cites·30 claims
- 0286US9493740B2Immunotherapy of cancer using genetically engineered GD2-specific T cellsBRENNER MALCOLM·Filed 2011·Granted Nov 15, 2016·25 cites·5 claims
- 0381US11725061B2CSGP4—specific chimeric antigen receptor for cancerBAYLOR COLLEGE MEDICINE·Filed 2018·Granted Aug 15, 2023·1 cites·18 claims
- 0475US12428490B2Methods and compositions for chimeric antigen receptor targeting cancer cellsUNIV NORTH CAROLINA CHAPEL HILL·Filed 2019·Granted Sep 30, 2025·1 cites·27 claims
- 0572US2024277764A1Targeting the Tumor Microenvironment Using Manipulated NKT CellsBAYLOR COLLEGE MEDICINE·Filed 2023·Application pending·0 cites
- 0669US2020369743A1Methods and compositions for chimeric antigen receptor targeting cancer cellsUNIV NORTH CAROLINA CHAPEL HILL·Filed 2019·Application pending·0 cites
- 0768US10519214B2Methods and compositions for chimeric antigen receptor targeting cancer cellsUNIV NORTH CAROLINA CHAPEL HILL·Filed 2019·Granted Dec 31, 2019·0 cites·22 claims
- 0863US2025127897A1Natural killer t-cells and methods of using the sameUNIV NORTH CAROLINA CHAPEL HILL·Filed 2023·Application pending·0 cites
- 0963US2025163178A1Methods and compositions for chimeric antigen receptor targeting cancer cellsUNIV NORTH CAROLINA CHAPEL HILL·Filed 2025·Application pending·0 cites
- 1063US2016376375A1CSGP4 - Specific Chimeric Antigen Receptor for CancerBAYLOR COLLEGE MEDICINE·Filed 2014·Application pending·0 cites
- 1156US2021106622A1Targeting the tumor microenvironment using manipulated nkt cellsMETELITSA LEONID S·Filed 2020·Application pending·0 cites
- 1256US2024108721A1Dual targeting chimeric antigen receptorsUNIV NORTH CAROLINA CHAPEL HILL·Filed 2021·Application pending·0 cites
- 1356US2021220403A1Targeting the tumor microenvironment using manipulated nkt cellsMETELITSA LEONID S·Filed 2020·Application pending·0 cites
- 1454US12410260B2Highly modular biepitopic and bispecific CAR-T cells for cancer immunotherapyUNIV NORTH CAROLINA CHAPEL HILL·Filed 2020·Granted Sep 9, 2025·0 cites·4 claims
- 1553US2025325640A1Methods for enhancing adoptive cell transfer immunotherapiesHansa Biopharma AB·Filed 2022·Application pending·0 cites
- 1652US2023127263A1Modified t cells and methods of preparing the sameUNIV NORTH CAROLINA CHAPEL HILL·Filed 2020·Application pending·0 cites
- 1752US2023136350A1Enhanced viral transduction of mammalian cells using material scaffoldsUNIV NORTH CAROLINA STATE·Filed 2021·Application pending·0 cites
- 1852US2024156864A1Methods and compositions for chimeric antigen receptor targeting cancer cellsUNIV NORTH CAROLINA CHAPEL HILL·Filed 2020·Application pending·0 cites
- 1950US2023263890A1Treatment of cd30-positive cancerTESSA THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 2049US2022354972A1In situ recruitment, reprogramming, and release of car-t cellsUNIV NORTH CAROLINA STATE·Filed 2020·Application pending·0 cites
- 2148US2014255363A1Targeting the tumor microenvironment using manipulated nkt cellsMETELITSA LEONID S·Filed 2012·Application pending·0 cites
- 2246US2023242666A1Methods and Compositions for the Reduction of Chimeric Antigen Receptor Tonic SignalingCELL MEDICA INC·Filed 2021·Application pending·0 cites
- 2344US2017027988A1Immunotherapy of cancer using genetically engineered gd2-specific t cellsBAYLOR COLLEGE MEDICINE·Filed 2016·Application pending·0 cites
- 2442US2013071414A1Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignanciesDOTTI GIANPIETRO·Filed 2012·Application pending·0 cites
- 2542US2016017048A1Targeting cd138 in cancerBAYLOR COLLEGE MEDICINE·Filed 2014·Application pending·0 cites
- 2634US2016017302A1Heparanase expression in human t lymphocytesBAYLOR COLLEGE MEDICINE·Filed 2014·Application pending·0 cites
- 2732US2017281683A1Glypican-3 specific chimeric antigen receptors for adoptive immunotherapyBAYLOR COLLEGE MEDICINE·Filed 2015·Application pending·0 cites
- 2829US2017335290A1Survivin specific t-cell receptor targeting tumor but not t cellsBAYLOR COLLEGE MEDICINE·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →